Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Zevra Therapeutics, and Poseida Therapeutics. According to TipRanks, Corwin has an average return of 4.1% and a 50.79% ...

PTC Therapeutics (NASDAQ:PTCT) has received FDA approval for its gene replacement therapy Kebilidi for the treatment of ...

Currently, the analyst consensus on PTC Therapeutics is a Hold with an average price target of $42.40, a -5.1% downside from current levels. In a report issued on November 7, RBC Capital also ...

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...

It’s an exciting time because our products are at the epicenter of driving business transformation at our customers,” said Neil Barua, President and CEO, PTC (PTC).

PTC earlier this month reported its fiscal year 2022 financials. For the year, which ended September 30, the company reported revenue of $1.93 billion, up 7 percent year over year. The company is ...

This collaboration will integrate Configit's Configuration Lifecycle Management (CLM) solutions with PTC's Product Lifecycle Management (PLM) systems, offering a comprehensive and cohesive ...

Future of Healthcategory Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free November 13, 2024 ...

Integration of CLM and PLM enables a streamlined approach to configuration management, leading to faster time to market and more satisfied customers COPENHAGEN, Denmark, Nov. 1, 2024 /PRNewswire/ ...